[1]Shaheen NJ, Falk GW, Iyer PG, Gerson LB ; American College of Gastroenterology. ACG Clinical Guideline : Diagnosis and Management of Barrett's Esophagus. Am J Gastroenterol 2016 ; 111 (1) : 30-50 ; quiz 51.
[2]Fitzgerald R.C., di Pietro M., Ragunath K. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut. 2014;63:7-42. British Society of Gastroenterology1
[3]Weusten B, Bisschops R, Coron E, et al. Endoscopic management of Barrett's esophagus : European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy 2017 ; 49 (2) : 191-198.
[4]Schlemper R.J., Riddell R.H., Kato Y. The Vienna classification of gastrointestinal epithelial neoplasia. Gut. 2000;47:251-255. 2
[5]Sharma P., Dent J., Armstrong D. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology. 2006;131:1392-1399. 5
[6]The Paris endoscopic classification of superficial neoplastic lesions : esophagus, stomach, and colon : November 30 to December 1, 2002. Gastrointest Endosc 2003 ; 58(Suppl. 6) : S3-S43.
[7]Thota P.N., Sada A., Sanaka M.R. Correlation between endoscopic forceps biopsies and endoscopic mucosal resection with endoscopic ultrasound in patients with Barrett's esophagus with high-grade dysplasia and early cancer. Surg Endosc. 2017;31:1336-1341. 3
[8]Yang D., Zou F., Xiong S., Forde J.J., Wang Y., Draganov P.V. Endoscopic submucosal dissection for early Barrett's neoplasia : a meta-analysis. Gastrointest Endosc. 2018;87:1383-1393. 6
[9]Pech O., Behrens A., May A. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut. 2008;57:1200-1206. 9
[10]Belghazi K., van Vilsteren F.G.I., Weusten B.L.A.M., Meijer S.L., Bergman JJGHM, Pouw R.E. Long-term follow-up results of stepwise radical endoscopic resection for Barrett's esophagus with early neoplasia. Gastrointest Endosc. 2018;87:77-84. 1
[11]van Vilsteren FG, Pouw RE, Seewald S, et al. Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett's oesophagus with high-grade dysplasia or early cancer : a multicentre randomised trial. Gut 2011 ; 60 (6) : 765-73.
[12]Phoa K.N., Pouw R.E., van Vilsteren F.G.I. Remission of Barrett's esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study. Gastroenterology. 2013;145:96-104. 1
[13]Shaheen N.J., Sharma P., Overholt B.F. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med. 2009;360:2277-2288. 22
[14]Phoa K.N., van Vilsteren F.G., Weusten B.L. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: A randomized clinical trial. JAMA. 2014;311:1209-1217. 12
[15]Manner H., Rabenstein T., Pech O. Ablation of residual Barrett's epithelium after endoscopic resection: A randomized long-term follow-up study of argon plasma coagulation vs. surveillance (APE study). Endoscopy. 2014;46:6-12. 1
[16]Kelty C.J., Ackroyd R., Brown N.J., Stephenson T.J., Stoddard C.J., Reed M.W. Endoscopic ablation of Barrett's oesophagus : a randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation. Aliment Pharmacol Ther. 2004;20:1289-1296. 11-12
[17]Peerally MF, Bhandari P, Ragunath K, et al. Radiofrequency ablation compared with argon plasma coagulation after endoscopic resection of high-grade dysplasia or stage T1 adenocarcinoma in Barrett's esophagus: A randomized pilot study (BRIDE). Gastrointest Endosc. 2018 Aug 1.
[18]Manner H., May A., Kouti I., Pech O., Vieth M., Ell C. Efficacy and safety of Hybrid-APC for the ablation of Barrett's esophagus. Surg Endosc. 2016;30:1364-1370. 4
[19]Alvarez Herrero L., van Vilsteren F.G., Pouw R.E. Endoscopic radiofrequency ablation combined with endoscopic resection for early neoplasia in Barrett's esophagus longer than 10 cm. Gastrointest Endosc. 2011;73:682-690. 4
[20]Fujii-Lau LL, Cinnor B, Shaheen N, et al. Recurrence of intestinal metaplasia and early neoplasia after endoscopic eradication therapy for Barrett's esophagus : a systematic review and meta-analysis Endosc Int Open 2017 ; 5 (6) : E430-E449.
[21]Gray N.A., Odze R.D., Spechler S.J. Buried metaplasia after endoscopic ablation of Barrett's esophagus: A systematic review. Am J Gastroenterol. 2011;106:1899-1908. 11quiz 1909
[22]Pouw R.E., Künzli H.T., Bisschops R. Simplified versus standard regimen for focal radiofrequency ablation of dysplastic Barrett's oesophagus: A multicenter randomized controlled trial. Lancet Gastroenterol Hepatol. 2018;3:566-574. 8
[23]Ghorbani S., Tsai F.C., Greenwald B.D. Safety and efficacy of endoscopic spray cryotherapy for Barrett's dysplasia: Results of the National Cryospray Registry. Dis Esophagus. 2016;29:241-247. 3
[24]Künzli H.T., Schölvinck D.W., Meijer S.L., Seldenrijk K.A., Bergman J.G.H.M., Weusten B.L.A.M. Efficacy of the CryoBalloon Focal Ablation System for the eradication of dysplastic Barrett's esophagus islands. Endoscopy. 2017;49:169-175. 2
[25]van Munster SN, Overwater A, Haidry R, Bisschops R, Bergman JJGHM, Weusten BLAM. Focal cryoballoon versus radiofrequency ablation of dysplastic Barrett's esophagus : impact on treatment response and postprocedural pain. Gastrointest Endosc. 2018 Jun 19.
[26]Cotton C.C., Haidry R., Thrift A.P., Lovat L., Shaheen N.J. Development of Evidence-Based Surveillance Intervals After Radiofrequency Ablation of Barrett's Esophagus. Gastroenterology. 2018;155:316-326. 2